Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $973 from $995 and keeps a Buy rating on the shares. The firm is updating its ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

Hims & Hers Health is down ~3% in Friday morning trading after an analyst note from BofA Securities stated that the company's ...

The stock market rebounded to or above key levels on tame inflation data and strong bank earnings. Many stocks flashed buy ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...

In the fourth quarter of 2024, the Baird Chautauqua International Growth Fund Net Investor Class returned -4.31%, ...

Hims & Hers (HIMS) is down -6.5%, or -$1.81 to $26.13.Stay Ahead of the Market:Discover outperforming stocks and invest smarter with Top ...

On the macro front, building permits decreased by 0.7% month-on-month in December to a seasonally adjusted rate of 1.48m, ...